ArticleProstate cancer and prostatic diseases2025
Incidence of prostate cancer in transgender women in the US: a large database analysis.
Article in Prostate cancer and prostatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Rates and Outcomes of Head and Neck Cancer Among Patients With Primary Immunodeficiency Disorders.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2026Article
- Prostatic diseases in transgender women: A systematic review of diagnosis, risk, and management.International journal of transgender health · 2026Review
- Impact of Prostate Cancer Treatment on Quality of Life of LGBTQ+ Patients: A Systematic Review.The world journal of men's health · 2025Review
- Tracking Epigenetic Biomarkers of Health and Aging During the Initial Year of Gender-Affirming Hormone Therapy.The Yale journal of biology and medicine · 2025Article
- Rethinking prostate cancer screening in transgender women Bridging the gap in inclusive healthcare.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Review
- Letter to the editor: "Incidence of prostate cancer in transgender women in the US: a large database analysis."Prostate cancer and prostatic diseases · 2025Article
- Gender Reassignment and the Role of the Laboratory in Monitoring Gender-Affirming Hormone Therapy.Journal of clinical medicine · 2024Review
- Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of prostate cancer among transgender women undergoing medical and surgical gender-affirming interventions remains unclear, though up to a fivefold decreased risk has been reported in comparison to cisgender men. In this study, we conducted a comparative analysis of the risk of prostate cancer among transgender women (TW) using data from TriNetX, a large database, versus SEER. Our findings indicate that, overall, transgender women exhibited a 2.56-fold lower risk of prostate cancer compared to cisgender men. Specifically, among TW on hormone therapy between ages 50-64, we observed a 2.06-fold decrease in risk. Contrary to the previous perception of prostate cancer being rare in transgender women, our study suggests that it may not be as uncommon as previously believed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.